Research News and Research

RSS

Major advance in understanding Friedreich's ataxia

University of Sydney researchers have made a significant advance in understanding the debilitating hereditary disease Friedreich's ataxia, offering hope that new forms of treatment will be developed.

8 Sep 2009

USA Today's 24-hour emergency room visit

A team of USA Today reporters spent a full, 24-hour day in the emergency room at University of Virginia Medical Center in late August. "The key elements of today's debate on health care converge in the ER, from the cutting-edge quality of the U.S. system to the millions of uninsured people who show up for care," according to the report. A key reform goal is covering an estimated 46 million uninsured Americans. But the task is expensive, and in many cases, born by ERs under the current system.

8 Sep 2009

Shalala, Cleveland Clinic's Cosgrove weigh in on current health debate

Two health care industry players have views about to handle the current overhaul debate.

8 Sep 2009

Republicans' changed stance on Medicare has historical roots

The GOP's change of stance on Medicare raises questions about its motives, The Associated Press reports in a separate story: "Weren't Republicans against Medicare before they were for it? It's a question vexing Democrats in the fierce battle over President Barack Obama's push for a health care overhaul as the head of the Republican Party has portrayed the GOP as the lone bulwark preventing deep cuts to the popular, government-run health plan for older people."

8 Sep 2009

Reform measures target health insurance practices such as dropping coverage

Health reform legislation seeks to eliminate practices used by insurance firms known as "rescissions," which firms defend as fraud control. The Washington Post reports in a story headlined "When Your Insurer Says You're No Longer Covered."

8 Sep 2009

Cytrx to submit revised protocol for arimoclomol Phase IIb clinical trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.

8 Sep 2009

Recipients of Charles C. Shepard Award announced

Jill Van Den Bos, a healthcare consultant in Milliman's Denver Health practice, and her colleagues from the Centers for Disease Control and Prevention (CDC) have been named recipients of the prestigious Charles C. Shepard Award.

8 Sep 2009

Haemonetics acquires SEBRA's blood collection and processing business

Haemonetics Corporation, a global blood management solutions company, and Engineering and Research Associates Inc. (known as "SEBRA(R)"), a leading provider of blood and medical manufacturing technologies, announced today that Haemonetics has acquired the assets of SEBRA's blood collection and processing business for $12.5 million cash. The acquisition is expected to close within the next several weeks.

8 Sep 2009

eBioscience Corporation announces the acquisition of NatuTec GmbH

eBioscience Corporation, a leading global provider of innovative, high-quality cell analysis reagents announced today the acquisition of NatuTec GmbH, a leading distributor of high-quality biological research reagents located in Frankfurt am Main, Germany.

8 Sep 2009

Exposure to air pollution can cause heart attack

It's well known that measures such as exercise, a healthy diet and not smoking can help reduce high blood pressure, but researchers at the University of Michigan Health System have determined the very air we breathe can be an invisible catalyst to heart disease.

8 Sep 2009

FDA undecided on safety guidelines for hydroquinone use

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the US market for physician-dispensed cosmeceutical pigment control products will experience considerable growth in sales over the next five years. MRG's US Markets for Physician-Dispensed Cosmeceuticals 2009 report finds, however, that product safety issues involving hydroquinone, the active ingredient in many pigment control products, have led the Food and Drug Administration (FDA) to second guess the use of the compound in such products.

8 Sep 2009

Powered SAFE Scribe hair replacement technique unveiled at ISHRS meeting

James A. Harris, M.D., director of Hair Sciences Center of Colorado, which specializes in state-of-the-art medical and surgical hair restoration, recently introduced to surgeons around the world his latest advancement in hair replacement, the Powered SAFE Scribe. The product was unveiled to the medical community during the 17th Annual Scientific Meeting of the International Society of Hair Restoration Surgery (ISHRS) held in late July in Amsterdam.

8 Sep 2009

Lab Research announces the signing of three new master services agreements with global companies

LAB Research Inc. ("LAB", "LAB Research" or the "Company"), (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced that it has entered into three new master services agreements with some of the most important global sponsors for each of the pharmaceutical, biotechnology and agro-chemical industries.

8 Sep 2009

New data fuels disagreements over regional Medicare spending

New data fuels some regional disputes on Medicare spending while some communities create better care and spend less than others. The New York Times reports that "new government data show that Medicare costs per patient in those cities [New York City, Boston] are slightly below the national average when the numbers are adjusted for the cost of living and other factors.

8 Sep 2009

Research to develop new techniques for studying wild and transgenic mice's nervous system

Researchers of the Pablo de Olavide University (Seville) have started different projects based on the study of phenotype techniques in mice and their applicability to the pharmaceutical industry and neurodegenerative medicine.

8 Sep 2009

RIKEN Yokohama Institute to purchase Genetic Analysis Systems from Helicos BioSciences

Helicos BioSciences Corporation (NASDAQ:HLCS) today announced that the RIKEN Yokohama Institute Omics Science Center (OSC) has agreed to purchase four Helicos™ Genetic Analysis Systems. The transaction represents the first multisystem sale of the Helicos system to a large genome center. Shipments are expected to take place in September, with one system remaining in Cambridge to be used in a scientific collaboration between the two parties that began last year.

8 Sep 2009

BEST bags orders for state-of-the-art synchrotron instrumentation

Bruker Energy & Supercon Technologies, Inc. (BEST) today announced that its subsidiary Bruker ASC GmbH in Bergisch Gladbach, Germany, has been awarded several significant contracts for state-of-the-art synchrotron instrumentation from leading research institutions worldwide.

8 Sep 2009

Working mothers suffer from vision impairment as they age

For working mothers -- the ultimate multitaskers -- seeing clearly is essential to getting the job done. Yet, new research reveals that as they age, changes in their vision are impacting the ability of most moms to perform everyday activities at home and on the job.

8 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

CEO Cancer Gold Standard accreditation for Independence Blue Cross

Philadelphia-based Independence Blue Cross has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

8 Sep 2009